Effect of Jardiance on glucose uptake into astrocytomas.
Chiara GhezziBenjamin M EllingsonAlbert LaiJie LiuJorge R BarrioErnest M WrightPublished in: Journal of neuro-oncology (2024)
These initial experiments show that SGLT2 is a functional glucose transporter in astocytomas, and Jardiance inhibited glucose uptake, a drug approved by the FDA to treat type 2 diabetes mellitus (T2DM), heart failure, and renal failure. We suggest that clinical trials be initiated to determine whether Jardiance reduces astrocytoma growth in patients.
Keyphrases
- heart failure
- clinical trial
- blood glucose
- end stage renal disease
- ejection fraction
- newly diagnosed
- glycemic control
- prognostic factors
- randomized controlled trial
- patient reported outcomes
- cardiovascular disease
- drug induced
- insulin resistance
- cardiovascular risk factors
- phase ii
- study protocol
- open label
- weight loss